Interim report 1 January – 30 September 2024

Organic growth and stable margin while profitability improvement initiatives are progressing


  
Continued organic growth and stable margin in the third quarter - a quarter that is normally somewhat weaker seasonally. The work on profitability improvements is progressing according to plan. 
   

Fredrik Dalborg, President and CEO 

1 JULY– 30 SEPTEMBER 2024 (3 MONTHS)

  • Net sales increased by 1% to SEK 2,344m (2,319). The organic growth, excluding exchange rate changes, was 3% and the acquired growth was 1%. 
  • EBITA decreased by 9% to SEK 223m (244), corresponding to an EBITA-margin of 9.5% (10.5). Adjusted for revalued contingent considerations and restructuring costs, EBITA amounted to SEK 230m (227), corresponding to an EBITA-margin of 9.8% (9.8).
  • Profit after tax amounted to SEK 25m (26).
  • Earnings per share amounted to SEK 0.19 (0.20).
  • Cash flow from operating activities amounted to SEK 137m (138).
  • During the quarter an acquisition, BonsaiLab SLU, was completed. The acquisition is estimated to contribute with an annual net sale of approximately SEK 90m.

1 JANUARY – 30 SEPTEMBER 2024 (9 MONTHS)

  • Net sales increased by 5% to SEK 7,468m (7,141). The organic growth, excluding exchange rate changes, was 5%. 
  • EBITA decreased by 5% to SEK 813m (857), corresponding to an EBITA-margin of 10.9% (12.0). Adjusted for revalued contingent considerations and restructuring costs, EBITA amounted to SEK 819m (756). Excluding these, EBITA increased by 8% and the EBITA-margin amounted to 11.0% (10.6).
  • Profit after tax amounted to SEK 160m (233).
  • Earnings per share amounted to SEK 1.30 (1.90). Earnings per share for the last 12 months amounted to SEK 0.98 (2.40)
  • Cash flow from operating activities amounted to SEK 429m (325).
  • The equity ratio was 40% (39).
  • Return on working capital (P/WC) amounted to 47% (50).
  3 months ending 9 months ending 12 months ending
SEKm 30 Sep 24 30 Sep 23 change 30 Sep 24 30 Sep 23 change 30 Sep 24 31 Dec 23
Net sales 2,344 2,319 1% 7,468 7,141 5% 10,012 9,685
EBITA 223 244 -9% 813 857 -5% 1,091 1,135
EBITA-margin 9.5% 10.5%   10.9% 12.0%   10.9% 11.7%
Profit before tax 42 61 -32% 255 337 -24% 257 339
Profit for the period 25 26 -4% 160 233 -31% 119 192
Earnings per share before dilution, SEK 0.19 0.20 -5% 1.30 1.90 -32% 0.98 1.56
Earnings per share after dilution, SEK 0.19 0.20 -5% 1.30 1.90 -32% 0.98 1.56
Dynamisk graf: Net sales (SEKm)
Dynamisk graf: EBITA (SEKm)
  3 months ending 9 months ending
One-off costs, SEKm 30 Sep 24 30 Sep 23 30 Sep 24 30 Sep 23
Restructuring reserve Camanio Health -4 – -10 –
Revalued contingent consideration -3 17 4 101
Total one-off costs -7 17 -6 101
         
  3 months ending 9 months ending
Classification in income statement, SEKm 30 Sep 24 30 Sep 23 30 Sep 24 30 Sep 23
Selling expenses -1 – -2 –
Administrative expenses -1 – -3 –
Research and Development -2 – -5 –
Other operating income and expenses -3 17 4 101
Total one-off costs in the income statement -7 17 -6 101
Latest updated: 10/22/2024 2:43:16 PM by jamilah.wass@add.life
NEXT